This session offers a comprehensive and candid review of the evolution, current impact, and future direction of radiotheranostics, with a particular focus on PSMA targeted imaging and therapy in prostate cancer.

This presentation provides a comprehensive critique of the clinical and preclinical evidence for neoadjuvant immunotherapy. Emphasis is placed on sharpening the definition of immunotherapy, identifying its multi-compartmental effects, and its off-target effects.

Dr. Carmen Guerra presents on the persistent racial and ethnic disparities that exist in patient access to clinical trials in head and neck oncology.

This session addresses the initial steps required for building a radiopharmaceutical program. Crucial to starting a program is understanding the business case, which includes understanding the potential referral stream, reimbursement, personnel, space, and equipment costs to start a program.

There are many ongoing advances in patient safety in the context of radiation therapy delivery, clinical research on treatment options, and advanced techniques in radiotherapy delivery.

It is imperative that our HNSCC medical care team across specialties professional remain current in the state-of-the-art techniques (Knowledge).

This keynote examined how leadership, culture, and aligned incentives can accelerate medical innovation, drawing lessons from the rapid development of COVID 19 vaccines and their application to radiopharmaceutical therapies (RPTs).

This session reviews head and neck cancers from a patient perspective.

This session reviews head and neck cancers from a patient perspective.

This session will review the key takeaways from the 2023 Multidisciplinary Thoracic Cancers Symposium.